Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

NCT01403064 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

76

Enrollment

INDUSTRY

Sponsor class

Stopped due to lack of efficacy

Conditions

Oral Mucositis

Interventions

BIOLOGICAL: ALD518
DRUG: 0.9% saline

Sponsor

CSL Behring